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Abstract
Helicobacter pylori infection is supposed to be one of the major
causes of digestive and other diseases. Among a lot of invasive
and non-invasive methods for its detection, none is ideal. The
aim is an assessment of the Helicobacter pylori infection in the
stomach using breath test and comparison to other diagnostic
methods, as well as following up the effects of therapy.
In 17 patients with digestive discomfort, breath test, rapid ure-
ase test and histology were performed, while in 47 patients with
proven HP infection the effect of therapy was followed up using
breath test and clinical findings. Breath test was performed af-
ter per oral administration of the capsule of 14C urea (37 kBq).
Findings of the breath and urease tests were in accordance in 14/
/17 patients (83%) while breath test and histology in 16/17 patients
(94%). During follow-up of the therapeutic effects, breath test and
clinical findings were in accordance in 43/47 patients (98%).
Breath test can be useful in diagnosis but is a method of choice
in following up the patients after therapy for H. pylori infection,
because it is non-invasive, fast and precise.
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Introduction
Helicobacter pylori (HP) is probably the most common bac-
terial pathogen with an incidence of up to 50% in some parts of
the world. Occurrence of the disease attributed to the pres-
ence of this bacterium depends on the infection, as well as on
the immune response and predisposition of the patient. Sequel
can include chronic superficial gastritis, duodenal or gastric
ulceration, gastric adenocarcinoma and mucosa-associated
lymphoid tissue lymphoma. Also, the presence of Helicobacter
pylori can be connected with some non-digestive diseases (is-
chaemic heart disease, autoimmune diseases, late puberty,
delayed growing-up etc.) [1].
H. pylori has a unique way of adapting in the stomach envi-
ronment. It goes through the mucous layer to infect gastric epi-
thelial cells, and produces enzymes that break down substanc-
es in gastric juice. The most important of these enzymes is ure-
ase. Urease converts urea from saliva and gastric juices into
bicarbonate and ammonia, which are strong bases and thus
protect bacteria from stomach acidity. The by-product-carbon
dioxide-is absorbed into the circulation and exhaled. Urease is
found in much higher concentrations in H. pylori than in any oth-
er bacteria, which enables performance of an accurate, sensi-
tive, specific and non-invasive diagnostic test. Thus, when an
infected patient swallows a dose of urea labelled with an isotope
14C Helicobacter pylori in the gastric mucosa break down the
labelled urea to form ammonia and labelled carbon dioxide, which
is being absorbed and exhaled. After the collection of a certain
amount of 14CO2, beta counter measures the radioactivity.
14C  is a low energy beta-emitter (49 keVmean, 156 keVmax) with
maximal range in water of 0.3 mm and physical half-life of 5730
years. 14CO2 reaches the maximal activity in the exhaled air after
1015 min, decreasing during time with biological half life of
T‰ = 15 min. 
14C urea which was not broken up is excreted by
urine with T‰ = 12 h, while 10% of 
14C remains in the body after
72h and is excreted with T‰ = 40 dana [2].
 14C-urea that is not
broken up by bacteria is eliminated by urine.
The aim of this study is detection of the presence of Helico-
bacter pylori, correlation of the results with other methods (fast ure-
ase test, pathohistology), as well as monitoring of the therapy re-
sponse in the infected patients by breath test and clinical findings.
Material and methods
We investigated two groups of patients. In the first one, con-
sisting of 17 patients with digestive discomfort, breath test, rap-
id urease test and histology were performed, and findings corre-
lated. In the other group, consisting of 47 patients with proven
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infection with Helicobacter pylori, the effect of therapy was fol-
lowed up using breath test and clinical findings. Initial therapy
consisted of a combination of two antibiotics (metronidazol,
clarithromycin, amoxycillin) plus proton pump inhibitors, during
seven days. If the infection persisted after a month following the
end of the therapy, the combination of antibiotics (azytromycin)
was changed, and used with colloid bismuth, proton pump in-
hibitors or H2 antagonists.
Four biopsy samples were taken from the antral mucosa for
pathohistology and fast urease test. Radionuclide breath test was
performed using commercial kit (capsules and vials containing
trapping solution-Helizo, Izotop, Hungary). It was done before
(background value estimation) and 30 minutes after per oral ad-
ministration of the capsule containing 14C urea (37 kBq). The pa-
tients exhaled in the KOH solution (with timolphtalein) until it be-
came colourless, which was the sign that a certain amount (1 mmol)
of CO2 had been trapped. After adding the 15 ml of scintillation
fluid (Ecolite ICN-Biomedicals), radioactivity in the collected sam-
ples before and after ingestion of the capsule was measured by
(LKB Wallac  Rack Beta Spectral) liquid scintillation counter,
during 5 minutes.
Results
According to our results, the rise of activity over 100% was
considered positive. From 17 patients, 7 were breath test posi-
tive, 9 negative and one equivocal. Fast urease test was positive
in 6, negative in 11, while histology was positive in 7 and negative
in 10 (Table 1). Findings of the breath and urease tests were in
accordance in 14/17 patients (83%) while breath test and histolo-
gy in 16/17 patients (94%).
During follow-up of the therapeutic effects, breath test and
clinical findings were in accordance in 43/47 patients (98%).
Discussion
Our results point out that the rise of activity over 100% in com-
parison to the background may be considered as a positive find-
ing, and that the results correlate with the ones obtained by other
methods. Also, we confirmed the value of the method in the fol-
low-up of the effects of therapy, thus excluding the need for the
use of invasive methods.
Our results are in accordance with the results of other au-
thors. So, Kaul [3] obtained very significant rise of the radioac-
tivity in the collected samples in Helicobacter positive persons
(p < 0.001). Jensen [4] proved that sensitivity and specificity
of the method are 100% in comparison to the fast urease test,
while in comparison to pathohistology 100% and 89% respec-
tively. The results of other authors point out [59] that sensitiv-
ity and specificity of these investigations were 9098% and 87
100% in comparison with histology and the culture of biopsy
specimen.
14C-urea breath test is both sensitive and specific for H. py-
lori; it detects only urease-producing organisms and reflects
total gastric urease activity, and results are reproducible. It tells
whether a patient is actively infected, and it can be used for
follow-up the treatment. However, it is necessary to perform the
investigation at least 4 weeks after the end of the antibiotic ther-
apy and two weeks after the therapy with sucralfates or proton
pump inhibitors in order to avoid false negative finding [10].
Also, caution is needed in the interpretation of the findings in
the patients with gastric resection, which can be false negative
because of the fast elimination of the capsule or false positive
because of achlorhydria or colonisation with Helicobacter-like
bacteria, which can also break up urea. The investigation must
be done at least 6 hours after the last meal. Some authors con-
clude that the radiation dose absorbed by a patient can be
compared to the one received from natural radiation sources
during one day [5, 11, 12], while the most pessimistic criteria
claim [4] that the dose absorbed in this way can be compared
to the one absorbed during radiography of the teeth (up to 20
µSv). Caution is necessary in implementation of the method in
pregnant and nursing women but it can [2] be performed with-
out risk in children.
Besides 14C-urea breath test, non-invasive methods for the
detection of Helicobacter pylori are 13C-urea breath test as well as
serologic analysis. The 13C isotope is not radioactive and so is saf-
er, although expensive instruments, which are not widely available,
are required to detect it. Serologic tests can tell only if infection has
occurred within the past year, not whether the patient is currently
infected. Endoscopy and biopsy require unpleasant medical pro-
cedures, and laboratory analysis. They can detect current infection
only if they hit an area in which the mucosa is infected, because of
its patchy distribution. Besides, this method carries a certain risk of
re-infection with Helicobacter pylori from the oral cavity.
14C-urea breath test can be used in diagnosis, but is a meth-
od of choice in following up the effect of therapy in patients with
Helicobacter pylori infection, because it is non-invasive, rapid, sen-
sitive, specific and available.
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